SAN DIEGO, October 29, 2015 – ProSciento, Inc., an early phase clinical research organization (CRO) focused on diabetes and obesity, looks forward to JDRF’s Walk to Cure Diabetes on Saturday, November 7 in Balboa Park. This year marks ProSciento’s 11th year walking and fundraising as a corporate team of employees and supporters and also its 11th year as a corporate sponsor.
Type 1 diabetes is an autoimmune disease in which a person’s pancreas loses the ability to produce insulin — a hormone essential to turning food into energy. It strikes both children and adults suddenly and is unrelated to diet and lifestyle. It requires constant carbohydrate counting, blood-glucose testing, and lifelong dependence on injected insulin. With type 1 diabetes there are no days off, and there is no cure. That’s why JDRF holds more than 200 Walks across the country every year to raise money to support research efforts to find a cure.
“The event itself is truly inspirational when witnessing so many people and businesses united together for a cause as vitally important as finding a cure and better treatments for type 1 diabetes,” said Dr. Marcus Hompesch, ProSciento President and CEO. “ProSciento is proud to be teaming up with JDRF to support the type 1 diabetes community and its Walk to Cure Diabetes fundraising event here in San Diego.”
About ProSciento, Inc.
ProSciento is a metabolism-focused, full scope clinical R&D services provider, with a mission to advance the global development of novel therapeutics for diabetes, NASH and obesity. The company is widely recognized for quality and scientific excellence, an unparalleled methodological toolkit, and extensive experience with virtually all metabolic drug and device classes. Utilizing its scalable R&D services model – combining deep therapeutic area expertise, strategic planning, an unparalleled methodological tool kit, and operational execution from late preclinical to phase III readiness – ProSciento provides highly customizable services for its global client base in today’s rapidly evolving landscape of metabolic drug and device development. For more information, please visit www.prosciento.com.
For media inquiries, please contact:
Abby Devine
Senior Director, Corporate Communications, ProSciento, Inc.
Tel: +1 858 663-6148
abby.devine@prosciento.com
For business development inquires:
bd@prosciento.com
For clinical study enrollment inquires:
Tel: +1 (866) 308-7427
volunteer@prosciento.com
